Vector-borne diseases (VBDs) pose significant public health challenges in India, with their management requiring a multifaceted approach. This article aims to provide a comprehensive review of the prevalence and strategies for controlling these diseases.
India, with its diverse climatic and geographical conditions, serves as a breeding ground for various vectors, leading to a high incidence of VBDs. Malaria, Dengue, and Chikungunya are the most common, contributing to significant morbidity and mortality. As per the National Vector Borne Disease Control Programme (NVBDCP), India reported approximately 331,058 malaria cases and 101,192 Dengue cases in 2019, demonstrating the scale of the problem.
The management of VBDs in India is fraught with challenges. These include a lack of comprehensive surveillance systems, inadequate diagnostic facilities, and limited access to effective treatment in remote areas. Moreover, the resistance of vectors to insecticides and parasites to drugs has further complicated the issue.
India's strategy for controlling VBDs involves an integrated approach that includes disease surveillance, early detection, prompt treatment, and vector control measures. The NVBDCP has implemented various programs like the National Malaria Control Program and the National Dengue Control Program to combat these diseases. The government is also promoting community participation and inter-sectoral coordination for effective VBD management.
Despite the challenges, significant progress has been made in managing VBDs in India. However, there is a need for more robust surveillance systems, improved diagnostic facilities, and effective treatment strategies. Healthcare professionals play a crucial role in this endeavor, and their active participation in disease control programs can significantly reduce the burden of VBDs in India.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation